CD8A and neoplasm: In a dual DBCO-adjuvant/antigen approach,combined administration of DBCO-CpG with DBCO-E7-peptide (derivedfrom human papillomavirus (HPV) E7 oncoprotein) also led to highernumbers of E7-tetramer+ CD8+ T-cells and interferon(IFN)-γ+ CD8+ T-cells with apparentlyfull protection from an E7-expressing TC-1 tumor challenge in a prophylacticstudy.